摘要
目的:探讨痛风饮颗粒治疗高尿酸血症肾损害的可能作用机制。方法:将50只昆明种雄性小鼠随机分为正常对照组、模型对照组、苯溴马隆组、别嘌醇组、痛风饮颗粒组,每组10只。除正常对照组外,其余4组采用腺嘌呤联合尿酸酶抑制剂氧嗪酸钾灌胃的方法建立小鼠高尿酸血症肾损害的模型,造模周期21 d。造模开始后第7天,按组别给予不同的干预药物,实验第22天,检测小鼠尿尿酸、尿β2微球蛋白水平和血尿酸、尿素氮水平,并取小鼠肾脏行HE染色,光镜观察病理变化。结果:痛风饮颗粒组小鼠血尿酸、尿素氮及尿β2微球蛋白水平均显著降低,与模型组比较有统计学意义(P <0. 05);同时尿尿酸水平显著升高,与模型组比较有统计学差异(P <0. 05)。病理学观察显示痛风饮颗粒可减轻肾小管的损伤及肾间质炎性细胞的浸润程度。结论:痛风饮颗粒能够改善尿酸代谢、促进尿酸排泄、减轻高尿酸血症肾脏病理损害。
Objective:To explore the possible mechanism of Tongfeng Yin Granule in treatment of kidney damage from hyperuricemia.Methods:50 male Kunming mice were randomly divided into normal control group,model control group,phenylbrommaron group,allopurinol group,Tongfeng Yin Granule group,each group of 10 mice.In addition to the normal control group,the models of kidney damage in mice with hyperuricemia were established by means of adenine combined with uric acid enzyme inhibitor potassium oxazinate.On the 7 th day after modeling,different intervention drugs were given by group.In the 22 nd day of the experiment,urine was taken to detect uric acid and urine β2-microglobulin levels in mice,and blood was taken to detect blood uric acid and urea nitrogen levels in mice.And take mice’s kidneys after anesthesia,after the pathological section,HE staining was performed,and the pathological changes of the kidneys were observed by light microscopy.Results:Tongfeng Yin Granule could significantly reduce the levels of serum uric acid,urea nitrogen,and urinary β2-microglobulin in mice with hyperuricemia kidney damage,which was statistically significant compared with the model group( P < 0.05);at the same time,the level of uric acid in mice could be significantly increased by Tongfeng Yin Granule,which was statistically different from the model group( P < 0.05).Pathologic observation results showed that Tongfeng Yin Granule could reduce the damage of renal tubules and the infiltration degree of interrenal cells.Conclusion:Tongfeng Yin Granule can promote uric acid excretion,improve the metabolism of uric acid,and improve the kidney pathological damage caused by hyperuricemia.
作者
于梅
周旋
姜泽宇
张拓
董云英
刘庆燕
姜国华
YU Mei;ZHOU Xuan;ZHANG Tuo;DONG Yunying;LIU Qingyan;JIANG Guohua(Heilongjiang Academy of Chinese Medical Sciences, Harbin, Heilongjiang 150001;Harbin Medical University, Harbin,Heilongjiang 150086;Heilongjiang University of Chinese Medicine,Harbin,Heilongjiang 150040)
出处
《中国中医药科技》
CAS
2019年第4期515-518,共4页
Chinese Journal of Traditional Medical Science and Technology
基金
黑龙江省中医药科研项目(ZHY18-030)